| Authors: |
Semmrich M; Department of Research, BioInvent International AB, Lund, Sweden., Marchand JB; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Fend L; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Rehn M; Department of Research, BioInvent International AB, Lund, Sweden., Remy C; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Holmkvist P; Department of Research, BioInvent International AB, Lund, Sweden., Silvestre N; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Svensson C; Department of Research, BioInvent International AB, Lund, Sweden., Kleinpeter P; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Deforges J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Junghus F; Department of Research, BioInvent International AB, Lund, Sweden., Cleary KL; Antibody and Vaccine Group, Centre for Cancer Immunology, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK., Bodén M; Department of Research, BioInvent International AB, Lund, Sweden., Mårtensson L; Department of Research, BioInvent International AB, Lund, Sweden., Foloppe J; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Teige I; Department of Research, BioInvent International AB, Lund, Sweden., Quéméneur E; Department of Research, Transgene SA, Illkirch-Graffenstaden, France., Frendéus B; Department of Research, BioInvent International AB, Lund, Sweden bjorn.frendeus@bioinvent.com.; Antibody and Vaccine Group, Centre for Cancer Immunology, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK. |
